Last reviewed · How we verify

ATGC Co., Ltd. — Portfolio Competitive Intelligence Brief

ATGC Co., Ltd. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Xeomin® Xeomin® marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery at neuromuscular junction) Neurology / Aesthetics
ATGC-110 ATGC-110 phase 3 PD-1 inhibitor PD-1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
  2. Addpharma Inc. · 1 shared drug class
  3. Asan Medical Center · 1 shared drug class
  4. Akeso · 1 shared drug class
  5. Amgen · 1 shared drug class
  6. Asahi Kasei Pharma Corporation · 1 shared drug class
  7. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  8. ASLAN Pharmaceuticals · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ATGC Co., Ltd.:

Cite this brief

Drug Landscape (2026). ATGC Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/atgc-co-ltd. Accessed 2026-06-09.

Related